| Primary |
| Product Used For Unknown Indication |
52.8% |
| Thrombosis Prophylaxis |
22.2% |
| Drug Use For Unknown Indication |
5.6% |
| Dyslipidaemia |
5.6% |
| Lipids Abnormal |
5.6% |
| Type Ii Hyperlipidaemia |
5.6% |
| Hypercholesterolaemia |
2.8% |
|
| Urticaria |
21.4% |
| Diabetes Mellitus Non-insulin-dependent |
14.3% |
| Vomiting |
14.3% |
| Coeliac Disease |
7.1% |
| Convulsion |
7.1% |
| Diabetes Mellitus |
7.1% |
| Drug Interaction |
7.1% |
| Heart Rate Increased |
7.1% |
| High Density Lipoprotein Decreased |
7.1% |
| Lactic Acidosis |
7.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
29.4% |
| Product Used For Unknown Indication |
14.2% |
| Diabetes Mellitus |
13.7% |
| Depression |
5.9% |
| Pemphigus |
4.9% |
| Lymph Node Tuberculosis |
4.4% |
| Angina Pectoris |
3.9% |
| Blood Cholesterol Increased |
3.9% |
| Dyslipidaemia |
2.9% |
| Tachyarrhythmia |
2.9% |
| Type Ii Hyperlipidaemia |
2.9% |
| Non-small Cell Lung Cancer |
2.0% |
| Cardiac Failure Congestive |
1.5% |
| High Density Lipoprotein Decreased |
1.5% |
| Antiretroviral Therapy |
1.0% |
| Blood Pressure Management |
1.0% |
| Blood Triglycerides Abnormal |
1.0% |
| Epilepsy |
1.0% |
| Insomnia |
1.0% |
| Premedication |
1.0% |
|
| Lactic Acidosis |
10.0% |
| Renal Failure Acute |
10.0% |
| Cushing's Syndrome |
6.7% |
| Liver Function Test Abnormal |
6.7% |
| Rhabdomyolysis |
6.7% |
| Tachyarrhythmia |
6.7% |
| Unevaluable Event |
6.7% |
| Vascular Pseudoaneurysm |
6.7% |
| Anaphylactic Reaction |
3.3% |
| Anaphylactic Shock |
3.3% |
| Angina Pectoris |
3.3% |
| Blood Cholesterol Increased |
3.3% |
| Cardiac Arrest |
3.3% |
| Completed Suicide |
3.3% |
| Coronary Arterial Stent Insertion |
3.3% |
| Diarrhoea |
3.3% |
| Haemangioma Of Liver |
3.3% |
| Haemolytic Anaemia |
3.3% |
| Hepatic Steatosis |
3.3% |
| Hypoglycaemia |
3.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
25.0% |
| Product Used For Unknown Indication |
18.0% |
| Rheumatoid Arthritis |
9.2% |
| Vitamin Supplementation |
6.8% |
| Multiple Sclerosis |
6.7% |
| Hypertension |
5.0% |
| Blood Cholesterol |
4.3% |
| Blood Cholesterol Increased |
3.8% |
| Medical Diet |
2.8% |
| Mineral Supplementation |
2.5% |
| Type 2 Diabetes Mellitus |
2.1% |
| Pain |
1.8% |
| Myocardial Infarction |
1.7% |
| Hyperlipidaemia |
1.7% |
| Prophylaxis |
1.7% |
| Depression |
1.6% |
| Diabetes Mellitus |
1.5% |
| Cardiovascular Event Prophylaxis |
1.4% |
| Raynaud's Phenomenon |
1.3% |
| Skin Ulcer |
1.3% |
|
| Vomiting |
13.0% |
| Pulmonary Tuberculosis |
7.6% |
| Granulocytopenia |
5.4% |
| Incorrect Dose Administered |
5.4% |
| Myalgia |
5.4% |
| Rash |
5.4% |
| Resorption Bone Increased |
5.4% |
| Ventricular Fibrillation |
5.4% |
| Drug Ineffective |
4.3% |
| Flushing |
4.3% |
| Injection Site Pain |
4.3% |
| Interstitial Lung Disease |
4.3% |
| Respiratory Failure |
4.3% |
| Urinary Tract Infection |
4.3% |
| Wound Infection |
4.3% |
| Accidental Exposure |
3.3% |
| Headache |
3.3% |
| High Density Lipoprotein Decreased |
3.3% |
| Pain |
3.3% |
| Subdural Empyema |
3.3% |
|
| Interacting |
| Depression |
23.7% |
| Diabetes Mellitus |
23.7% |
| Drug Use For Unknown Indication |
17.8% |
| Tachyarrhythmia |
11.9% |
| Blood Cholesterol Increased |
5.9% |
| Dyslipidaemia |
5.9% |
| High Density Lipoprotein Decreased |
5.9% |
| Product Used For Unknown Indication |
2.2% |
| Anticoagulant Therapy |
1.5% |
| Lipids Abnormal |
1.5% |
|
| Myocardial Infarction |
72.7% |
| International Normalised Ratio Increased |
18.2% |
| Drug Interaction |
9.1% |
|
